-
Most Popular
Search Results
240 results for dgse
Carnival Stock Sees A Strong Rally But Is It Worth Your Time?
CCL stock sees a strong rally after a double dose of vaccine news but investors should still proceed with caution on this investment.
Inovio Stock Is Still a Strong Coronavirus-Related Bet to Make
Inovio is speeding toward a vaccine for the coronavirus and has plans to make 1 million doses by the end of the year to boost…
Gilead Sciences Is a Strong Buy Despite What Its Detractors Might Say
Gilead Sciences is donating 1.5 million doses of remdesivir, which has many analysts bullish on GILD stock now.
Why Amazon.com, Inc., Ford Motor Company and Helmerich & Payne, Inc. Are Today’s 3 Worst Stocks
Falling oil prices, disappointing earnings and a healthy dose of Wall Street skepticism sent these three big names lower Friday.
Rigel Pharmaceuticals, Inc. (RIGL) Up Nearly 50% on Study Results, Price Target Increase
Rigel Pharmaceuticals, Inc. (RIGL) is flying high today after two doses of good news, as the stock strayed into overbought territory.
AK Steel: The Charts Are Turning Around for AKS Stock
Tuesday’s earnings-driven rally in AKS stock appears to have given the charts of AK Steel a dose of momentum with a chance to last.
Novavax Is a Vaccine Investment That You Shouldn’t Ignore
It makes sense to hold your NVAX stock shares now as Novavax is working hard to promote the distribution of its Covid-19 vaccine doses.
5 Stocks With Awful Earnings Momentum — LVNTA WRK CZR GLP RGSE
This week, these five stocks have the worst ratings in Earnings Momentum, one of the eight Fundamental Categories on Portfolio Grader.
FDA Pulls Approval for a Generic Antidepressant
A generic version of antidepressant Wellbutrin has lost FDA approval after tests showed it less effective than the brand name drug at a certain dosage.
Novavax Stock Is a Buy Even After the Company’s Post-Dip Bounce
NVAX stock seems attractive for accumulation in the recent correction. Vaccine focus on low-income countries is likely to deliver growth.
CureVac Is a Bet on a Safe and Effective Vaccine
CureVac is a bet on a winning Covid-19 vaccine that is effective and safe. Buying CureVac stock could produce a 27.5% annual compounded return over…
Moderna Stock Is Worth Much More
Moderna reaps the rewards of its Covid-19 vaccine, and MRNA stock is worth 57% to 172% more based on near-term and long-term earnings power.
Pfizer May Have Found a New Hit Drug
The drug company’s new medication could be a game-changer. See what it treats and why one analyst thinks it’s a home run.
Ocugen Just Overcame a Serious Hurdle
OCGN stock has skyrocketed on positive Phase 3 results. But the company is facing tough competition.
The Vaccine Race Is Far From Over, And That’s Good News for Novavax
Bill Gates expects Novavax’s vaccine to be effective against Covid-19. Despite Pfizer being first, NVAX stock is still bound to benefit.
ALT Stock Alert: Altimmune Pops on Weight-Loss Drug Findings
Altimmune (ALT) stock is soaring and trending after the company reported data on its GLP-1 weight-loss drug today.
Why Is Dyne Therapeutics (DYN) Stock Up 39% Today?
Dyne Therapeutics stock is rising higher on Wednesday as investors in DYN react to positive clinical trial news from the company.
Wave Life Sciences News: WVE Stock Crashes 50% on Huntington’s Disease Data
Wave Life Sciences (WVE) news for Monday has WVE stock taking a beating on early data from its Huntington’s disease trial.
Alphabet Should Be on Every Technology Investor’s Radar Now
Skeptics might claim the Google search engine is “dead,” but a dose of common sense should get investors to lean bullish on GOOG stock.
Revelation Biosciences (REVB) Stock Soars 120%
REVB stock is soaring 120%, but no news explains the rally. The firm recently finished dosing patients for a trial of its hay fever drug.
Meet Your New Robot Overlords – Morning Linkfest (June 6)
InvestorPlace’s daily dose of some of the best reads elsewhere on Wall Street. Today’s top stories: robots, goats and junk bonds.
Novavax Stock is Set to Soar in the Year Ahead
The potential rewards in NVAX stock far outweigh the risks as the vaccine maker awaits regulatory approval from the WHO and others.
3 – 10 of 240 results
